SmartCella Holding AB
Nelly Rahkonen has extensive experience in the field of stem cell research and process development. Currently serving as Process Development Manager and previously as Senior Scientist at Procella Therapeutics AB since January 2019, Nelly's career includes roles as a Postdoctoral Researcher at Karolinska Institutet from August 2015 to January 2019, where work focused on human stem cell derived cardiomyocytes, and at the University of Turku from 2014 to July 2015, concentrating on pluripotent human embryonic stem cells. Earlier experience includes a Graduate Student position at Turku Centre for Biotechnology, researching the regulation of self-renewal and karyotypic changes of pluripotent human embryonic stem cells from 2007 to 2013, and a prior role as a Project Engineer. Nelly holds a Doctor of Philosophy (PhD) in Human Embryonic Stem Cells and a Master of Science (M.Sc.) in Health Biosciences, Drug Development from the University of Turku, along with a Bachelor of Engineering (B.E.) in Biotechnology from Turku University of Applied Sciences.
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.